Highlights WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Market Closed - Canadian Securities Exchange Other stock markets 09:49:31 2022-06-28 am EDT			5-day change	1st Jan Change
0.045 ^CAD	-.--%		-.--%	-.--%

Feb. 05	WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Feb. 02	WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Feb. 05	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Feb. 02	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	Jan. 30	CI
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline	23-05-01	CI
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy	23-01-17	CI
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)	22-12-18	CI
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin	22-12-05	CI
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	22-05-16	CI
WPD Pharmaceuticals Inc. Signs Consortium Agreement on EuroNanoMed Project	22-03-07	CI
WPD Pharmaceuticals Inc. Secures Berubicin Sub-License Rights in Perpetuity	22-02-01	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Wpd Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in Second Half of 2021	21-06-28	CI
WPD Pharmaceuticals Inc. Joins International Research Consortium	21-06-10	CI
Wpd Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-06-03	CI
WPD Pharmaceuticals Inc. Receives $6.7 Million Grant for Development of Annamycin Drug Candidate	21-05-11	CI
WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101	21-03-16	CI
WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials	21-02-24	CI
WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study	21-02-18	CI
Wpd Pharmaceuticals Inc. Engages Worldwide Clinical Trials as Cro for Further Support on Berubicin Trials	21-02-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Highlights

Filters